More French drug price cuts in store as 'stability programme' gets green light
This article was originally published in SRA
Executive Summary
The French pharmaceutical industry is again under the hammer. Parliament has passed a package of measures including proposals to slice €10bn of healthcare spending over the 2015-17 period – some €3.5bn of which will affect medicines, and probably medical devices – in the form of selected price cuts, together with moves to increase the market share of generics.